Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells

Cancer Research

Volumn 59, Issue 4, 1999, Pages 886-894

  Hosoi, Hajime ^a,c   Dilling, Michael B ^a   Shikata, Takuma ^a   Liu, Linda N ^a   Shu, Lili ^a   Ashmun, Richard A ^a   Germain, Glen S ^a   Abraham, Robert T ^b,d   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53; RAPAMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL SURVIVAL; CHEMOSENSITIVITY; DRUG BINDING; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

APOPTOSIS; BINDING SITES; CARRIER PROTEINS; G1 PHASE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RHABDOMYOSARCOMA; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033557578     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. 1-arresting rapamycin receptor complex. Nature (Lond.), 369: 756-758, 1994.
2. Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., and Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78: 35-43, 1994.
3. Chiu, M. I., Katz, H., and Berlin, V. RAPT1, a mammalian homolog of yeast TOR, interacts with the FKBP/rapamycin complex. Proc. Natl. Acad. Sci. USA, 91: 12574-12578, 1994.
4. Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., and Abraham, R. T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem., 270: 815-822, 1995.
5. Chung, J., Grammer, T. C., Lemon, K. P., Kazlauskas, A., and Blenis, J. PDGF-and insulin-dependent pp70S6K activation mediated by phosphatidylinositol-3OH kinase. Nature (Lond.), 370: 71-75, 1994.
6. Monfar, M., Lemon, K. P., Grammer, T. C., Cheatham, L., Chung, J., Vlahos, C. J., and Blenis, J. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol. Cell. Biol., 15: 326-337, 1995.
7. Kulik, G., Klippel, A., and Weber, M. J. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol., 17: 1595-1606, 1997.
8. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (Washington DC), 275: 661-665, 1997.
9. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H., and Downward, J. Matrix adhesion and Ras transformation both activate phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J., 16: 2783-2793, 1997.
10. 1 phase of the cycle. J. Cell. Physiol., 154: 7-15, 1993.
11. 1/S transition. Ann. N. Y. Acad. Sci., 696: 31-37, 1993.
12. 1 arrest point in MG-63 cells. Ann. N. Y. Acad. Sci., 696: 54-61, 1993
13. Schreiber, S. L. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science (Washington DC), 251: 283-287, 1991.
14. Molnar-Kimber, K. L. Mechanism of action of rapamycin (sirolimus, rapamune). Transplant. Proc. 28: 964-969, 1996.
15. Abraham, R. T., and Wiederrecht, G. J. Immunopharmacology of rapamycin. Annu. Rev. Immunol., 14: 483-510, 1996.
16. Francavilla, A., Starzl, T. E., Carr, B., Azzarone, A., Carrieri, G., Zeng, Q. H., and Porter, K. A. The effects of FK506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. Transplant. Proc., 23: 2817-2820, 1991.
17. Marx, S. O., Jayaraman, T., Go, L. O., and Marks, A. R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circulation Res., 76: 412-417, 1995.
18. Jayaraman, T., and Marks, A. R. Rapamycin-FKBP blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. J. Biol. Chem., 268: 25385-25388, 1993.
19. Akselband, Y., Harding, M. W., and Nelson, P. A. Rapamycin inhibits spontaneous and fibroblast growth factor-stimulated proliferation of endothelial cells and fibroblasts. Transplant. Proc., 23: 2833-2836, 1991.
20. 1 of an osteosarcoma cell line. J. Biol. Chem., 268: 22825-22829, 1993.
21. Dilling, M. B., Dias, P., Shapiro, D. N., Germain, G. S., Johnson, R. K., and Houghton, P. J. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res., 54: 903-907, 1994.
22. Seufferlein, T., and Rozengurt, E. Rapamycin inhibits constitutive p70S6K phosphorylalion, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res., 56: 3895-3897, 1996.
23. Dumont, F. J., Melino, M. R., Staruch, M. J., Koprak, S. L., Fischer, P. A., and Sigal, N. H. The immunosuppressive macrolides FK-506 and raparaycin act as reciprocal antagonists in murine T cells. J. Immunol., 144: 1418-1424, 1990.
24. Bierer, B. E., Mattila, P., Standaert, R., Herzenberg, L., Burakoff, S., Crabtree G. R., and Schreiber, S. L. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. USA, 87: 9231-9235, 1990.
25. Flanagan, W. M., Carthésy, B., Bram, R. J., and Crabtree, G. R. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature (Lond.), 352: 803-807, 1991.
26. McCaffrey, P. G., Luo, C., Kerpola, T. K., Jain, J., Badalian, T. M., Ho, A. M., Burgeon., E., Lane, W. S., Lambert, J. N., Curran, T., Verdine, G. L., Rao, A., and Hogan, P. G. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science (Washington DC), 262, 750-754, 1993.
27. McCaffrey, P. G., Perrino, B. A., Soderling, T. R., and Rao, A. NF-ATp, a T lymphocyte DNA-binding protein thai is a target for calcineunn and immunosuppressive drugs. J. Biol. Chem., 268: 3747-3752, 1993.
28. Brown, E. J., Beal, P. A. Keith, C. T. Chen, J., Shin, T. B., and Schreiber, S. L. Control of p70S6 kinase by kinase activity of FRAP in vivo. Nature (Lond.), 377: 441-446, 1995.
29. Chung, J., Kuo, C. J., Crabtree, G. R., and Blenis, J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell, 69: 1227-1236, 1992.
30. S6K. Nature (Lond.), 358: 70-73, 1992.
31. P70S6K in IL-2 and mitogen activated human T cells. Biochem. Biophys. Res. Commun., 186: 1315-1321, 1992.
32. Price, D. J., Grove, J. R., Calvo, V., Avruch, J., and Bierer, B. E. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science (Washington DC), 257: 973-977, 1992.
33. Lin, T-A., Kong, X., Haystead, T. A. J., Pause, A. S., Belsham, G., Sonenberg, N., and Lawrence, J. C., Jr. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science (Washington DC), 266: 653-656, 1994.
34. Graves, L. E., Bomfeldt, K. E., Argast, G. M., Krebs, E. G., Kong, X., Lin, T-A., and Lawrence, J. C., Jr. cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc. Natl. Acad. Sci. USA, 92: 7222-7226, 1995.
35. Pause, A., Belsham, G. J., Gingras, A-C., Donze, O., Lin, T-A., Lawrence, J. C., Jr., and Sonenberg, N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature (Lond.), 371: 762-767, 1994.
36. vonManteuffel, S. R., Dennis, P. B., Pullen, N., Gingras, A-C., Sonenberg, N., and Thomas, G. The insulin-induced signaling pathway leading to S6 and initiation factor 4E binding protein I phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70S6K. Mol. Cell. Biol., 17: 5426-5436, 1997.
37. Pullen N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A., and Thomas, G. Phosphorylation and activation of p70S6K by PDK1. Science (Washington DC), 279: 707-710, 1998.
38. Burnett, P. E. Barrow, R. K., Cohen, N. A., Snyder, S. H., and Sabatini, D. M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BPI. Proc. Natl. Acad. Sci. USA. 95: 1432-1437, 1998.
39. Terada, N., Franklin, R. A., Lucas, J. L., Blenis, J., and Gelfand, E. W. Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J. Biol. Chem., 268: 12062-12068, 1993.
40. Calvo, V., Wood, M., Gjertson, C., Vik, T., and Bierer, B. E. Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation. Eur. J. Immunol., 24: 2664-2671, 1994.
41. Brunn, G. J., Hudson, C. C., Sekulic, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., Jr., and Abraham, R. T. Phosphorylation of the eukaryotic initiation factor-4E-binding protein. PHAS-I, by the mammalian target of rapamycin. Science (Washington DC), 277: 99-104, 1997.
42. Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K., Weng Q. P., Kasuga, M., Nishimoto, I., and Avruch, J. Regulation of elF-4E BP1 phosphorylation by mTOR. J. Biol. Chem., 272: 26457-26463, 1997.
43. Jefferies, H. B., Reinhard, J. C., Kozma, S. C., and Thomas, G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc. Natl. Acad. Sci. USA, 91: 4441-4445, 1994.
44. Terada, N., Patel, H. R., Takase, K., Kohno, K., Nairn, A. C. and Gelfand, E. W. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc. Natl. Acad. Sci. USA, 91: 11477-11481, 1994.
45. Sonenberg, N. mRNA 5′ cap-binding protein elF4E and control of cell growth. In: J. W. B. Hershey, M. B. Mathews, and N. Sonenberg (eds.), Translational Control, pp. 245-269. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1996.
46. Nielsen, F. C., Ostergaard, L., Nielsen, J., and Christiansen, J. Growth-dependent translation of IGF-II mRNA by a rapamycin-sensitive pathway. Nature (Lond.), 377: 358-362, 1995.
47. Rosenwald, I. B., Kaspar, R., Rousseau, D., Gehrke, L., Lebulch, P., Chen, J-J., Schmidt, E. V., Sonenberg, N., and London, I. M. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriplional and post-transcriptional levels. J. Biol. Chem., 270, 21176-21180, 1995.
48. kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (Lond.), 372: 570-573, 1994.
49. kip1. Mol. Cell. Biol., 16: 6744-6751, 1996.
50. Mendez, R., Myers, M. G., Jr., White, M. F., and Rhoads, R. E. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol. Cell. Biol., 16: 2857-2864, 1996.
51. Muthukkumar, S., Ramesh, T. M., and Bondada, S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 60: 264-270, 1995.
52. Ishizuka, T., Sakata, N., Johnson, G. L., Gelfand, E. W., and Terada, N. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. Biochem. Biophys. Res. Commun., 230: 386-391, 1997.
53. Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., and Miller, G. B. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res., 55: 1982-1988, 1995.
54. Gibson, A. A., Harwood, F. G., Tillman, D. M., and Houghton, J. A. Selective sensitization to DNA-damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression. Clin. Cancer Res., 4: 145-152, 1998.
55. Mashiyama, S., Murakami, Y., Yoshimoto, T., Sekiya, T., and Hayashi, K. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene, 6: 1313-1318, 1991.
56. Chen, J., Zheng, X. F., Brown, E. J., and Schreiber, S. L. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue Proc. Natl. Acad. Sci. USA, 92: 4947-4951, 1995.
57. El-Badry, O. M., Minniti, C., Kohn, E. C., Houghton, P. J., Daughaday, W. H., and Helman, L. J. Insulin like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ., 1: 325-331, 1990.
58. Hosoi, H., Dilling, M. B., Liu, L. N., Danks, M. K., Shikata, T., Sekulic, A., Abraham, R. T., Lawrence, J. C. Jr., and Houghton, P. J. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol. Pharmacol., 54: 815-824, 1998.
59. Shapiro, D. N., Jones, B. G., Shapiro, L. H., Dias, P., and Houghton, P. J. Antisense-mediated reduction in insulin-like growth factor-1 receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J. Clin. Invest., 94: 1235-1242, 1994.
60. Resnicoff, M., Burgaud, J., Rotman, H. L., Abraham, D., and Baserga, R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor 1 receptors. Cancer Res., 55: 3739-3741, 1995.
61. Resnicoff, M., Abraham, D., Yutanawiboonchai, W., Rotman, H. L., Kajstura, J., Rubin, R., Zoltick, P., and Baserga, R. The insulin-like growth factor receptor protects tumor cells from apoptosis in vivo. Cancer Res., 55, 2463-2469, 1995.
62. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J., 13: 3286-3295, 1994.
63. Dunn, S. E., Hardman, R. A., Kari, F. W., and Barrett, J. C. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res., 57: 2687-2693, 1997.
64. Polunovsky, V. A., Rosenwald, I. B., Tan, A. T., White, J., Chiang, L., Sonenberg, N., and Bitterman, P. B. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-facto-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol. Cell. Biol., 16: 6573-6581, 1996.
65. Sigal, N. H., Dumont, F. J., Siekierka, J. J., Wiederrecht, G., Parent, S. A., and Brizuela, L. Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK506? Transplant. Proc. 23: 2846-2849, 1991.